Keap1 loss promotes Kras-driven lung cancer and results in a dependence on glutaminolysis

Treating KRAS-mutant lung adenocarcinoma (LUAD) remains a major challenge in cancer treatment given the difficulties associated with directly inhibiting the KRAS oncoprotein(1). One approach to addressing this challenge is to define frequently co-occurring mutations with KRAS, which themselves may l...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Nat Med
Main Authors: Romero, Rodrigo, Sayin, Volkan I., Davidson, Shawn M., Bauer, Matthew R., Singh, Simranjit X., LeBoeuf, Sarah E., Karakousi, Triantafyllia R., Ellis, Donald C., Bhutkar, Arjun, Sanchez-Rivera, Francisco J., Subbaraj, Lakshmipriya, Martinez, Britney, Bronson, Roderick T., Prigge, Justin R., Schmidt, Edward E., Thomas, Craig J., Goparaju, Chandra, Davies, Angela, Dolgalev, Igor, Heguy, Adriana, Allaj, Viola, Poirier, John T., Moreira, Andre L., Rudin, Charles M., Pass, Harvey I., Vander Heiden, Matthew G., Jacks, Tyler, Papagiannakopoulos, Thales
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5677540/
https://ncbi.nlm.nih.gov/pubmed/28967920
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nm.4407
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki